2-Chloro-6-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol → 1-(4-(6-(3-Aminopyrrolidin-1-yl)pyridin-3-ylamino)-6-(3-chloro-5-fluoro-4-hydroxyphenyl)quinolin-3-yl)propan-1-one
Reaction equation
Br[C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12](=[O:15])[CH2:13][CH3:14])=[C:5]2[NH:16][C:17]1[CH:18]=[CH:19][C:20]([N:23]2[CH2:27][CH2:26][CH:25]([NH:28]C(=O)OC(C)(C)C)[CH2:24]2)=[N:21][CH:22]=1.[Cl:36][C:37]1[CH:42]=[C:41](B2OC(C)(C)C(C)(C)O2)[CH:40]=[C:39]([F:52])[C:38]=1[OH:53]>>[NH2:28][CH:25]1[CH2:26][CH2:27][N:23]([C:20]2[N:21]=[CH:22][C:17]([NH:16][C:5]3[C:4]4[C:9](=[CH:10][CH:11]=[C:2]([C:41]5[CH:40]=[C:39]([F:52])[C:38]([OH:53])=[C:37]([Cl:36])[CH:42]=5)[CH:3]=4)[N:8]=[CH:7][C:6]=3[C:12](=[O:15])[CH2:13][CH3:14])=[CH:18][CH:19]=2)[CH2:24]1Participants
Reactant 2
Product 1
Procedure
Following general procedure D, tert-butyl 1-(5-(6-bromo-3-propionylquinolin-4-ylamino) pyridin-2-yl)pyrrolidin-3-ylcarbamate (100 mg, 0.18 mmol) was reacted with 2-chloro-6-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (76 mg, 0.28 mmol) to obtain the protected intermediate which was subjected to general procedure A-2 to afford the desired product (34 mg, 37% over two steps) as a yellow solid: 1H NMR (500 MHz, CD3OD+TFA-d) δ 9.29 (s, 1H), 8.29-8.18 (m, 2H), 8.06-7.99 (m, 2H), 7.82 (dd, J=9.1, 2.6 Hz, 1H), 7.16-7.10 (m, 1H), 7.07 (s, 1H), 6.97 (d, J=9.1 Hz, 1H), 4.17-4.08 (m, 1H), 4.06-3.98 (m, 1H), 3.90-3.81 (m, 1H), 3.79-3.70 (m, 2H), 3.27-3.19 (m, 2H), 2.64-2.53 (m, 1H), 2.35-2.25 (m, 1H), 1.26 (t, J=7.1 Hz, 3H); ESI MS m/z 506 [C27H25ClFN5O2+H]+; HPLC>99% (AUC), tR=10.75 min.
Workup
- customto obtain the protected intermediate which
Sources & evidence
- ORD record
- ord-1f8f459491864851ac06129e2f005fd8
- Source dataset
- uspto-grants-2015_09
- Patent number
- US09120749B2
Reaction notes
Loading…